Ovarian cancer is the most lethal of all gynecological malignancies, and the identification of novel prognostic and therapeutic targets for ovarian cancer is crucial. It is believed that only a small subset of cancer cells are endowed with stem cell properties, which are responsible for tumor growth, metastatic progression and recurrence. NANOG is one of the key transcription factors essential for maintaining self-renewal and pluripotency in stem cells. This study investigated the role of NANOG in ovarian carcinogenesis and showed overexpression of NANOG mRNA and protein in the nucleus of ovarian cancers compared with benign ovarian lesions. Increased nuclear NANOG expression was significantly associated with high-grade cancers, serous histological subtypes, reduced chemosensitivity, and poor overall and disease-free survival. Further analysis showed NANOG is an independent prognostic factor for overall and disease-free survival. Moreover, NANOG was highly expressed in ovarian cancer cell lines with metastasis-associated property and in clinical samples of metastatic foci. Stable knockdown of NANOG impeded ovarian cancer cell proliferation, migration and invasion, which was accompanied by an increase in mRNA expression of E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1. Conversely, ectopic NANOG overexpression enhanced ovarian cancer cell migration and invasion along with decreased E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1 mRNA expression. Importantly, we found Nanogmediated cell migration and invasion involved its regulation of E-cadherin and FOXJ1. This is the first report revealing the association between NANOG expression and clinical outcome of patients with ovarian cancers, suggesting NANOG to be a potential prognostic marker and therapeutic molecular target in ovarian cancer.
INTRODUCTION
Ovarian cancer is a common gynecological cancer worldwide and contributes to high mortality, despite advances in treatment modalities. 1 The poor prognosis is due to lack of symptoms at early stages until widespread metastasis develops and high rates of chemoresistance found in patients with advanced diseases. 2 In consequence, it is vital to identify novel prognostic markers and therapeutic targets for ovarian cancer.
NANOG is one of the core transcription factors expressed in pluripotent embryonic stem cells but not in somatic organs. 3, 4 NANOG has essential roles in maintaining self-renewal and the undifferentiated state of pluripotent stem cells during early embryonic development. Besides controlling such 'stemness' properties, the role of NANOG in tumorigenesis has attracted attention. 5 Increasing evidence has suggested that most tumors are heterogeneous. Of which, a small subset of cells, known as cancer stem cells, arise from mutated adult stem/progenitor cells possessing stem cell-like properties, which are responsible for tumor growth, metastasis, chemoresistance and thus cancer recurrence. Only by targeting these population of cells, which exhibit a number of important phenotypic, biological and functional characteristics associated with normal stem cells, one can ultimately cure the disease. 6, 7 Therefore, cancer stem cell markers, which are good therapeutic targets in common cancers, are being vigorously investigated. 8, 9 Recent studies have identified and characterized a self-renewing subpopulation of cancer-initiating cells in ovarian cancers endowed with stem cell-like properties and induced NANOG expression. [9] [10] [11] In addition, NANOG expression has also been found in an ovarian cancer cell line and is involved in multidrug resistance. 12 In this study, we investigated the prognostic significance of NANOG in ovarian cancer and assessed for the first time the functional roles and putative downstream targets of NANOG in ovarian cancer. Our results suggest that NANOG may be one of cancer stem cell markers that have a central role in the progression of ovarian cancers. As such, NANOG could also be an important prognostic marker for identifying patients who respond better to current treatment regimes, as well as a therapeutic target for ovarian cancer treatment.
RESULTS NANOG is overexpressed in the nucleus of ovarian cancers and associated with tumor aggressiveness, metastasis and chemosensitivity By immunohistochemistry, no nuclear NANOG immunostaining was detected in benign cystadenomas, whereas weak to moderate expression was found in borderline tumors and ovarian cancers, respectively (Figure 1a) . In terms of the percentage of positive cells, around 2-20% cancer cells were stained in borderline tumors and ovarian cancers, respectively ( Table 1) . The differential nuclear NANOG immunoreactivity (that is, histoscore as mentioned in Materials and Methods) among the three diagnostic categories, including benign, borderline and carcinomas, were statistically significant (P ¼ 0.031; Table 1 ). Moreover, statistically higher nuclear NANOG immunoreactivity was found in metastatic foci than their corresponding primary carcinomas (P ¼ 0.005; Figure 1a and Table 1 ). High nuclear NANOG immunoreactivity was significantly associated with poor histological grade, serous histological subtypes and chemosensitivity (all Po0.05; Table 1 ). Similar trend was also obtained when percentage, but not intensity, of NANOG-stained cells was used for analyses (Table 1) . Significantly higher NANOG mRNA levels were also found in ovarian cancers than in benign cystadenomas as detected by quantitative PCR (qPCR; P ¼ 0.046; Figure 1bi ). The result also revealed that the mRNA expression of SOX-2 and OCT-4, two other core stem cell transcription factors, 13 was also overexpressed in ovarian cancers (Figure 1bii and iii).
NANOG overexpression is associated with poor prognosis of ovarian cancer patients Univariate analysis revealed that NANOG was significantly associated with shorter overall (P ¼ 0.001) and disease-free (P ¼ 0.002) survival (Figure 2 ). Similar trends were also observed when either intensity or percentage of NANOG immunoreactive cells was used for analyses (data not shown). By multivariate Figure 1 . Overexpressed NANOG in ovarian cancer associated with tumor aggressiveness, metastasis and chemosensitivity. (a) Immunohistochemical staining of NANOG in serous benign cystadenomas (i), serous borderline tumors (ii), serous carcinomas (iii) with corresponding metastatic foci (iv), mucinous benign cystadenomas (v), mucinous borderline tumors (vi), mucinous carcinomas (vii), endometrial carcinomas (viii), clear cell carcinomas (ix), chemosensitive (x) and chemoresistant (xi) ovarian carcinomas. Insets: highlighted regions with higher magnification. (b) qPCR analysis of (i) NANOG, (ii) SOX-2 and (iii) OCT-4 mRNA in ovarian tumors as shown in scatter plots with a line at mean. The fold change of the target gene expression was calculated with respect to the mean expression of the target gene in benign cystadenomas. analysis, NANOG, disease stage and chemosensitivity remained significant predictors for overall survival, whereas NANOG, disease stage and debulking remained significant predictors for diseasefree survival (all Po0.05; Supplementary Table 3) .
NANOG is overexpressed in ovarian cancer cell lines and localized in the nucleus of cancer cells By qPCR, NANOG mRNA expression was higher in 5 (OVCA 433, OVCAR-3, PA-1, SKOV-3 and SW626) and lower in 2 (OVCA 420 and TOV112D) out of 12 ovarian cancer cell lines, compared with the 3 normal HOSE cell lines. In particular, NANOG mRNA expression in SKOV-3 and OVCAR-3, two cell lines produced from metastatic ovarian cancers, was at least six-to eight-fold higher than the normal HOSE cell lines (Figure 3a) . Moreover, we found that NANOG mRNA expression was about nine-fold higher in 2008-C13 (cisplatin-resistance) than in the 2008 (cisplatin-sensitive) cell lines ( Figure 3b ). Subcellular expression of NANOG in nuclear and cytoplasmic fractions of OVCAR-3 was also determined by immunoblotting. Concurring with the immunohistochemical findings, NANOG protein expression was predominately found in the nuclear fraction, with no detectable expression in the cytoplasmic fraction ( Figure 3c ).
Knockdown of NANOG impedes ovarian cancer cell proliferation, migration and invasion, downregulates SOX-2 and upregulates E-cadherin and caveolin-1 mRNA expression Stable knockdown of NANOG in OVCAR-3 was detected at both mRNA and protein levels ( Figure 4a ). We found that stable knockdown of NANOG significantly retarded cell proliferation after 12 days (Figure 4b ). Moreover, Transwell migration and invasion assays revealed significantly reduced migration and invasion (Po0.05) in shNANOG OVCAR-3 compared with that in control ( Figure 4c ). In addition, specific transient (siNanog no. 1 and no. 2; Supplementary Figure 1a ) knockdown of NANOG in SKOV-3 significantly reduced migration and invasion (Supplementary Figure 1b) . Next, we investigated the effect of NANOG depletion on mRNA expression of SOX-2 and OCT-4, two other core stem cell transcription factors, 13 and E-cadherin, caveolin-1 and integrin-b1, all are possible downstream targets for cell migration and invasion. 14, 15 In fact, previous study documented that NANOG can bind to specific promoter elements of SOX-2, OCT-4, caveolin-1 and integrin-b1 in embryonic stem cells. 13 We found that depletion of NANOG expression in OVCAR-3 cells significantly decreased SOX-2, and upregulated E-cadherin and caveolin-1, but have no virtual effect on OCT-4 and integrin-b1 mRNA expression ( Figure 4d ). Moreover, upregulation of E-cadherin and caveolin-1 in protein level was also demonstrated in NANOG-depleted OVCAR-3 cells (Figure 4d, inset) . Transient knockdown of NANOG in SKOV-3 also significantly decreased SOX-2 and upregulated E-cadherin, but have no virtual effect on OCT-4, caveolin-1 and integrin-b1 mRNA expression (Supplementary Figure 1c) .
Knockdown of NANOG enhances FOXO1, FOXO3a, FOXJ1 and FOXB1 mRNA expression Forkhead box (FOX) proteins are a large family of transcriptional regulators, which control a variety of biological processes leading to alteration of cell fate, thus the development and progression of cancer. 16 As four FOX proteins, including FOXO1, FOXO3a, FOXJ1 and FOXB1, are the likely targets of NANOG in embryonic stem cells, 13 we investigated their mRNA expression Figure 1c) . Among them, increasing number of studies documented that FOXO are cellular targets of antitumor drugs in malignancies, including ovarian cancer. 16, 17 As a consequence, we further explored whether NANOG can regulate FOXO1 and FOXO3a transcription activities. Our results showed that both FOXO1 (Figure 5b Nanog-mediated cell migration and invasion involves E-cadherin and FOXJ1 To test if Nanog-mediated cell migration and invasion is dependent on E-cadherin and FOXJ1, NANOG-depleted OVCAR-3 cells were treated with specific small interfering RNAs (siRNAs) of E-cadherin and FOXJ1. E-cadherin and FOXJ1 mRNA expression was reduced by 80% in siRNA-treated cells when compared with control cells (Supplementary Figure 2) . Treatment with siRNAs against E-cadherin and FOXJ1 also increased basal cell migration and invasion, and rescued NANOG-reduced migration and invasion (Figure 5c ). Similar results were obtained when another set of siRNAs were used (data not shown). In addition, OVCA420 cells were transiently transfected with NANOG and E-cadherin (Figure 6d ). Ectopically expressed E-cadherin decreased cell migration and invasion, and inhibited NANOG-mediated migration and invasion (Figure 6e ).
DISCUSSION
In this study, we showed significantly higher NANOG immunoreactivity in ovarian cancer samples when compared with borderline tumors and benign cystadenomas/inclusion cysts. Expression of NANOG mRNA and that of two other core stem cell transcription factors, SOX-2 and OCT-4, was also detected in ovarian cancer. In vitro, we found that SOX-2 can be regulated by NANOG in ovarian cancer cells. Interestingly, in borderline tumor and ovarian cancer clinical samples, only around 2-20% cancer cells were NANOG-positive. Cancer stem cells are a small population of cells found in a given malignant tissue. 8 The present finding showing a small portion of NANOG-positive tumor cells in ovarian tumors concur with this property, suggesting NANOG is not only involved in ovarian cancer progression, but also may be one of cancer stem cell makers. In agreement, cancer stem-like cells isolated from ascites derived from ovarian cancer patients, 18 prostate tumors, 19 oral squamous cell carcinoma 20 and osteosarcoma 21 also showed elevated NANOG expression.
Significantly higher NANOG immunoreactivity was detected in poorly differentiated ovarian cancers, serous histological subtypes and in metastatic foci when compared with their corresponding primary ovarian cancers. In vitro, NANOG mRNA expression was also particularly high in SKOV3 and OVCAR-3, which are derived from the malignant ascites of patients diagnosed with serous adenocarcinoma. 22 These serous-type tumors account for B70% of ovarian cancers, 23 and are often associated with ascites formation and intraperitoneal metastases. 24 These findings suggest NANOG to be involved in ovarian cancer dedifferentiation and metastasis, which are two important cancer stem cell properties. 8, 19, 20 We also found lower NANOG mRNA expression in endometrioid tumor-derived TOV112D cell line 25 compared with the three normal HOSE cell lines, which is consistent with the relatively lower NANOG immunoreactivity in endometrioid ovarian cancers. More importantly, we demonstrated a significant correlation between high NANOG immunoreactivity and shorter overall and disease-free survival, suggesting NANOG to be an important prognostic marker in ovarian cancer. NANOG is an independent prognostic factor for overall survival. If high NANOG expression can be further confirmed to indicate poor prognosis, as suggested in this report, it may serve as a biomarker to assist in triage of patients with early-stage ovarian cancers and decision for adjunct therapy. Ovarian cancer patients diagnosed with stage I (confined to ovary) disease do not need adjuvant chemotherapy unless they are associated with poor prognostic parameters such as high-grade cancers (high-grade serous or clear cell types) or capsular involvement. Even under such situations, single-agent therapy by carboplatin can be administered instead of a combination with paclitaxel as in patients with higher-staged disease. Moreover, maintenance molecular-targeted therapy such as bevacizumab is also being investigated for patients with poor prognosis. High NANOG expression may serve as a marker for indicating combination instead of single-agent chemotherapy in stage I patients, as well as to select high-risk patients for administering adjunct-targeted therapy to improve their clinical outcome. Larger scale studies are needed to confirm such application.
Ovarian cancer-initiating cells isolated from primary tumors with overexpressed NANOG and other stem cell markers was shown to enhance chemoresistance to the ovarian cancer chemotherapeutics cisplatin or paclitaxel. 10 Cancer stem-like cells isolated from osteosarcoma also showed evaluated NANOG expression along with chemoresistance. 21 Moreover, Hyaluronan treatment of ovarian and breast cancer cells induced Stat-3 bound to NANOG and favored Stat-3-specific transcriptional activation, leading to MDR1 gene expression and multidrug resistance. 12 Thus, increasing evidence showed that conventional anticancer therapies are mostly unable to remove cancer stem cell clones and instead help cancer stem cell expand and/or select for resistant cancer stem cell clones, leading to cancer patient relapse. 8 In this study, significantly higher NANOG immunoreactivity in chemoresistant ovarian cancer samples and cell lines was detected. We also found upregulation of FOXO1 and FOXO3a transcription activities and mRNA levels after stable knockdown of NANOG in ovarian cancers, as well as downregulation of FOXO1 and FOXO3a mRNA expression in NANOG-overexpressing cells, suggesting NANOG to be a negative regulator of FOXO1 and FOXO3a. Given that FOXO transcription factors are cellular targets of anticancer drugs in multiple cancers 16, 17 and low FOXO3a expression is associated with poor prognosis in ovarian cancer patients, 26 it is possible that NANOG affect chemosensitivity through transcription regulation of FOXO1 and FOXO3a, which will be studied in near future.
Functionally, we found knockdown of NANOG reduced ovarian cancer cell proliferation, migration and invasion along with upregulated E-cadherin and caveolin-1, whereas ectopic overexpression of NANOG led to increased cell migration and invasion along with downregulated E-cadherin. We have previously reported positive effect of NANOG on choriocarcinoma cell migration and invasion. 27 In ovarian cancer cells, simultaneous expression of caveolin-1 and E-cadherin found to stabilize adherens junctions through inhibition of src-related kinases. 28 In contrast, depletion of E-cadherin promoted ovarian cancer metastasis through induced a5-integrin expression. 15 In vivo, NANOG expression pattern is opposite to E-cadherin expression in ovarian cancers, where reduced E-cadherin expression was found at metastatic sites when compared with their primary ovarian tumors. 29 Moreover, a significantly shorter survival was found in ovarian cancer patients with negative E-cadherin expression. 30 Importantly, our rescue experiments demonstrated Nanog-mediated cell migration and invasion in E-cadherin-dependent manner.
FOXJ1 has been found to suppress inflammation through repression of nuclear factor-kB. 31 Besides being an important mediator of immune response, nuclear factor-kB is also involved in regulating tumor growth, apoptosis and metastasis, thus tumorigenesis. FOXJ1 was hypermethylated in breast tumor cell lines and clinical samples, suggesting being a putative tumor suppressor gene. 32 Although the mechanisms through which FOXJ1 suppress tumor growth remains unknown, our findings implicate FOXJ1 as one of the downstream mediators of NANOG in regulating cell migration and invasion, and suggest that FOXJ1 suppress tumor progression through regulation on cellular processes in metastasis.
In conclusion, our in vivo and in vitro findings demonstrated NANOG, an important stem cell-related transcription factor, to be involved in ovarian tumorigenesis, probably through regulating chemosensitivity, cell proliferation, migration and invasion. NANOG is a negative regulator of E-cadherin and FOXJ1 in mediating ovarian cancer cell migration and invasion. Importantly, NANOG is a potential prognostic marker and molecular therapeutic target in ovarian cancer.
MATERIALS AND METHODS

Clinical samples
Archived formalin-fixed, paraffin-embedded tissue blocks in ovarian cancer, with the corresponding clinical follow-up data, were retrieved from the Department of Pathology, University of Hong Kong, Queen Mary Hospital, including 6 benign cystadenomas (age range 20-35 years, mean age 34.8 years), 7 borderline tumors (age range 20-46 years, mean age 28.9 years), 97 carcinomas (age range 32-83 years, mean age 50.5 years) with different histological subtypes and 43 corresponding metastatic foci of ovarian cancers for studying NANOG protein expression. Among patients with ovarian cancers, 80 received chemotherapy including platinum/paclitaxel after surgery, and the median follow-up period was 63 months (range, 4-209 months). Twenty-eight randomly selected ovarian tumor clinical samples, with available frozen blocks including three benign cystadenomas, and 25 ovarian cancer samples were also retrieved for studying mRNA expression of NANOG, SOX-2 and OCT-4. The use of these samples was approved by the Institutional Ethical Review Board. The diagnosis of each sample was assessed by pathologists and ensured to have more than 70% tumor cells.
Cell lines, subcellular protein extraction and treatment 35, 36 Cytoplasmic and nuclear extracts from OVCAR-3 cells were isolated using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockford, IL, USA). 33, 34 Stable knockdown of NANOG in OVCAR-3
Small hairpin RNA constructs targeting human NANOG (pRS-shNANOG with puromycin-resistant gene; Origen, Rockville, MD, USA) were stably transfected into OVCAR-3 cells using Lipofectamine 2000 (Invitrogen, San Diego, CA, USA), whereas pRS empty vector (pRS-shControl; Origen) transfected cells were used as control. 27, 33 Stable clones were selected with puromycin (1.875 mg/ml).
Transient knockdown of NANOG in SKOV-3 and E-cadherin and FOXJ1 in OVCAR-3 Cells were transfected with two siRNAs of NANOG, E-cadherin and FOXJ1 (Ambion, Austin, TX, USA) using SilentFect (Bio-Rad Laboratories, Hercules, CA, USA) per manufacturer's instructions for 48 h before cell counting and cell plating. Silencer Select Negative Control siRNA (Ambion) was used as control.
Ectopic overexpression of NANOG and E-cadherin in OVCA420
The pcDNA3.1-NANOG and pcDNA3.1-E-cadherin plasmids were obtained from Addgene (www.addgene.org). Cells were transfected with NANOG and E-cadherin or the control vector using PolyJet DNA In vitro Tranfection Reagent (SignaGen Laboratories, Rockville, MD, USA) for 48 h before cell counting and cell plating.
Immunohistochemistry
Immunohistochemical staining was performed as described. 27, 34 Antibody against NANOG (ab21603; Abcam, Cambridge, MA, USA) at a dilution of 1:50 was applied to deparaffinized sections, and tested using EnVision þ Dual Link System (K4061; Dako, Carpinteria, CA, USA). Antigen recovery was performed by heating in a pressure cooker using 10 mM EDTA (pH 8.0). Elimination or replacement of the primary antibody with preimmune IgG serum was acted as a negative control. Both the intensity and percentage of stained epithelial cells were evaluated semiquantitatively. Staining intensity was scored as 0 (negative), 1 (faint), 2 (moderate) and 3 (strong). The percentage of positive cells was rated as 0 (o5%), 1 (5-25%), 2 (26-50%), 3 (51-75%) and 4 (475%). Only nuclear staining was considered as positive. The immunoreactivity was assessed by multiplying the staining intensity by the percentage of stained cells to give a composite 'histoscore'. High-and low-expression levels of NANOG were defined by the 'histoscores' cut off at mean.
Real-time PCR (qPCR)
Total RNA extracted from cancer cell lines was reverse transcribed by SuperScript Reverse Transcriptase (Invitrogen). qPCR was done using ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA) as described. 27, 33 Primer sequences were listed in Supplementary  Table 1. Immunoblotting Protein lysate (20 mg) was resolved by SDS-polyacrylamide gel electrophoresis, electroblotted to polyvinylidene difluoride membrane, and hybridized with corresponding antibodies. 27, 34 Antibodies used in this study are listed in Supplementary Table 2. Cell proliferation was determined by cell count method Cells (3 Â 10 4 ) were seeded in T150 culture flasks and maintained in growth medium. 34 Cell number was counted using trypan blue dye exclusion with hematocytometer at day 12.
In vitro migration and invasion assays
In vitro migration and invasion assays were done as previously described. 27, 34 OVCAR-3 cells (1.25 Â 10 5 ) were plated on the upper side of a Transwell chamber. Cells migrated through an 8-mm pore size membrane and Matrigel-coated membrane (migration assay and invasion assay were assessed, respectively). After 24 (migration assay) or 48 h (invasion assay), cells on the upper compartment of the membrane were removed and the migrated or invaded cells at the lower surface of the membrane were fixed, stained and counted.
Luciferase reporter assay
Control and shNANOG OVCAR-3 cells were transiently transfected with pGL3-Basic empty vector (negative control), pGL3-Basic-FOXO1A-Luc (bp À 1609/ þ 230) or pGL3-Basic-FOXO3-Luc (bp 1480/ À 25) reporter plasmids. pRL-SV40-Luc was used as internal control. Cells were lysed 48 h post transfection. Luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) as previously described. 37 Transfection efficiency was normalized by Renilla luciferase activities.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA). Mann-Whitney test and Kruskal-Wallis rank test were used for comparison of data between two groups and among multiple groups, respectively. Kaplan-Meier analysis and log-rank test were used for survival analysis. Multivariate survival analysis was done using Cox regression analysis. P-values o0.05 were considered as statistically significant.
